Patents by Inventor Francois-Xavier MAUVAIS

Francois-Xavier MAUVAIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for determining whether a patient suffering from rhabdomyolysis achieves a response with a TLR9 antagonist
    Patent number: 11473145
    Abstract: The inventors initially participated to the identification of LPIN1 mutations as a cause for massive rhabdomyolysis episodes in children, triggered by febrile illness. The inventors have suggested that TLR9 antagonists would be suitable for the treatment of rhabdomyolysis (WO2017085115). The inventors thus treated 2 patients with lipin-1 disease by a TRL9 antagonist (hydroxychloroquine). They showed that the accumulation of mtDNA in plasma of the two patients before treatment decreases under treatment. When the treatment was stopped, the accumulation of mtDNA reappeared, then normalized when treatment was resumed. Accordingly, the present invention relates to a method for determining whether a patient suffering from rhabdomyolysis achieves a response with a TLR9 antagonist comprising determining the amount of mitochondrial DNA (mtDNA) in a blood sample obtained from the patient (e.g. by PCR).
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: October 18, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), FOUNDATION IMAGING, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ DE PARIS
    Inventors: Pascale De Lonlay-Debeney, Peter Van Endert, Marine Madrange, Yamina Hamel, François-Xavier Mauvais
  • METHODS FOR DETERMINING WHETHER A PATIENT SUFFERING FROM RHABDOMYOLYSIS ACHIEVES A RESPONSE WITH A TLR9 ANTAGONIST
    Publication number: 20210087633
    Abstract: The inventors initially participated to the identification of LPIN1 mutations as a cause for massive rhabdomyolysis episodes in children, triggered by febrile illness. The inventors have suggested that TLR9 antagonists would be suitable for the treatment of rhabdomyolysis (WO2017085115). The inventors thus treated 2 patients with lipin-1 disease by a TRL9 antagonist (hydroxychloroquine). They showed that the accumulation of mtDNA in plasma of the two patients before treatment decreases under treatment. When the treatment was stopped, the accumulation of mtDNA reappeared, then normalized when treatment was resumed. Accordingly, the present invention relates to a method for determining whether a patient suffering from rhabdomyolysis achieves a response with a TLR9 antagonist comprising determining the amount of mitochondrial DNA (mtDNA) in a blood sample obtained from the patient (e.g. by PCR).
    Type: Application
    Filed: July 26, 2018
    Publication date: March 25, 2021
    Inventors: Pascale DE LONLAY-DEBENEY, Peter VAN ENDERT, Marine MADRANGE, Yamina HAMEL, François-Xavier MAUVAIS
  • Methods and pharmaceutical compostions for treating rhabdomyolysis
    Patent number: 10653687
    Abstract: The present invention relates to methods and pharmaceutical compositions for treating rhabdomyolysis.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: May 19, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, FONDATION IMAGINE, UNIVERSITÉ PARIS DESCARTES ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pascale De Lonlay-Debeney, Corinne Lebreton, Yamina Hamel, Francois-Xavier Mauvais, Peter Van Endert
  • METHODS AND PHARMACEUTICAL COMPOSTIONS FOR TREATING RHABDOMYOLYSIS
    Publication number: 20180325890
    Abstract: The present invention relates to methods and pharmaceutical compositions for treating rhabdomyolysis.
    Type: Application
    Filed: November 16, 2016
    Publication date: November 15, 2018
    Inventors: Pascale DE LONLAY-DEBENEY, Corinne LEBRETON, Yamina HAMEL, Francois-Xavier MAUVAIS, Peter VAN ENDERT